Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer

被引：0
|
作者：
Hideaki Miyake
Yuto Matsushita
Hiromitsu Watanabe
Keita Tamura
Daisuke Motoyama
Toshiki Ito
Takayuki Sugiyama
Atsushi Otsuka
机构：
[1] Hamamatsu University School of Medicine,Department of Urology
来源：
International Journal of Clinical Oncology | 2019年 / 24卷
关键词：
Non-metastatic castration-resistant prostate cancer; First-generation antiandrogen; Androgen-receptor-axis-targeted agent; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：842 / 847
页数：5
相关论文
共 16 条
  • [1] Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer
    Miyake, Hideaki
    Matsushita, Yuto
    Watanabe, Hiromitsu
    Tamura, Keita
    Motoyama, Daisuke
    Ito, Toshiki
    Sugiyama, Takayuki
    Otsuka, Atsushi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (07) : 842 - 847
  • [2] Prognostic Outcomes and Predictive Factors in Non-Metastatic Castration-Resistant Prostate Cancer Patients Not Treated with Second-Generation Antiandrogens
    Wang, Yu-Jen
    Tseng, Chi-Shin
    Huang, Chao-Yuan
    Chen, Chung-Hsin
    Wang, So-Meng
    Huang, Kuo-How
    Chow, Po-Ming
    Pu, Yeong-Shiau
    Chueh, Jeff Shih-Chieh
    Chung, Shiu-Dong
    Cheng, Jason Chia-Hsien
    BIOMEDICINES, 2024, 12 (10)
  • [3] The prognostic superiority of second-generation androgen receptor signaling inhibitor in patients with non-metastatic castration-resistant prostate cancer
    Naiki, Taku
    Takahara, Kiyoshi
    Watanabe, Hiromitsu
    Nakane, Keita
    Sugiyama, Yosuke
    Koie, Takuya
    Shiroki, Ryoichi
    Miyake, Hideaki
    Yasui, Takahiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 55 (02) : 164 - 171
  • [4] Prognostic factors for non-metastatic castration-resistant prostate cancer treated with androgen receptor signaling inhibitors
    Takahara, Kiyoshi
    Naiki, Taku
    Nakane, Keita
    Watanabe, Hiromitsu
    Miyake, Hideaki
    Koie, Takuya
    Yasui, Takahiro
    Shiroki, Ryoichi
    MOLECULAR AND CLINICAL ONCOLOGY, 2024, 21 (04)
  • [5] YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients
    Afonso, Ana
    Silva, Jani
    Lopes, Ana Rita
    Coelho, Sara
    Patrao, Ana Sofia
    Rosinha, Alina
    Carneiro, Filipa
    Pinto, Ana Rita
    Mauricio, Maria Joaquina
    Medeiros, Rui
    PHARMACOGENOMICS, 2020, 21 (13) : 919 - 928
  • [6] Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer
    Chung, Doo Yong
    Ha, Jee Soo
    Cho, Kang Su
    BIOMEDICINES, 2021, 9 (06)
  • [7] Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer
    Kelly, Richard
    Anton, Angelyn
    Wong, Shirley
    Shapiro, Julia
    Weickhardt, Andrew
    Azad, Arun
    Kwan, Edmond Michael
    Spain, Lavinia
    Muthusamy, Arun
    Torres, Javier
    Parente, Phillip
    Parnis, Francis
    Goh, Jeffrey
    Joshua, Anthony
    Pook, David
    Baenziger, Olivia
    Gibbs, Peter
    Tran, Ben
    BJU INTERNATIONAL, 2021, 128 : 18 - 26
  • [8] Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer
    Kenichiro Fukuoka
    Jun Teishima
    Hirotaka Nagamatsu
    Shogo Inoue
    Tetsutaro Hayashi
    Koji Mita
    Masanobu Shigeta
    Kanao Kobayashi
    Mitsuru Kajiwara
    Yuichi Kadonishi
    Takatoshi Tacho
    Akio Matsubara
    International Urology and Nephrology, 2020, 52 : 77 - 85
  • [9] Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer
    Fukuoka, Kenichiro
    Teishima, Jun
    Nagamatsu, Hirotaka
    Inoue, Shogo
    Hayashi, Tetsutaro
    Mita, Koji
    Shigeta, Masanobu
    Kobayashi, Kanao
    Kajiwara, Mitsuru
    Kadonishi, Yuichi
    Tacho, Takatoshi
    Matsubara, Akio
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2020, 52 (01) : 77 - 85
  • [10] The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison
    Neal Shore
    Shan Jiang
    Viviana Garcia-Horton
    Emi Terasawa
    David Steffen
    Andi Chin
    Rajeev Ayyagari
    Jamie Partridge
    A. Reginald Waldeck
    Advances in Therapy, 2022, 39 : 5025 - 5042
12